Hasn't Anavex reported positively on its pre-specified amyloid 42/40 marker (corresponding to FDA Stage 1 and Stage 2), but not reporting hitting on either of the pre-specified elevated ptau 181 (stage 2 to 3 and beyond) or elevated NfL (stage 3/4 and beyond)? (I'm using your descriptions here.)
Market Data 
Markets 
AI
